McClain Value Management’s Enanta Pharmaceuticals ENTA Stock Holding History

McClain Value Management’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-37,810	Closed	-$2.22M	–	23
2017 Q4	$2.22M	Sell	37,810 -252	-0.7%	-$12.6K	2.93%	20
2017 Q3	$1.78M	Sell	38,062 -27,233	-42%	-$1.09M	2.51%	21
2017 Q2	$2.35M	Sell	65,295 -64,253	-50%	-$2.06M	3.03%	21
2017 Q1	$3.99M	Buy	129,548 +13,395	+12%	+$417K	5.12%	4
2016 Q4	$3.89M	Sell	116,153 -66,933	-37%	-$1.92M	4.8%	7
2016 Q3	$4.87M	Sell	183,086 -3,764	-2%	-$87.4K	3.91%	12
2016 Q2	$4.12M	Buy	186,850 +80,342	+75%	+$2.1M	3.51%	15
2016 Q1	$3.13M	Sell	106,508 -148,719	-58%	-$4.14M	2.47%	21
2015 Q4	$8.43M	Sell	255,227 -132,007	-34%	-$4.3M	3.02%	18
2015 Q3	$14M	Sell	387,234 -54,505	-12%	-$2.34M	4.42%	16
2015 Q2	$19.9M	Sell	441,739 -2,589	-0.6%	-$101K	4.95%	8
2015 Q1	$13.6M	Buy	+444,328	New	+$17.3M	3.23%	16

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

McClain Value Management's ENTA Position: Q1 2018 in Review

McClain Value Management sold out of Enanta Pharmaceuticals (ENTA) in Q1 2018, closing a stake of 37,810 shares — an estimated $2.22M sold.

McClain Value Management first reported a position in ENTA in Q1 2015 and held it in 12 quarters. The position peaked at $19.9M in Q2 2015. 181 funds tracked by Wall St. Rank hold ENTA as of Q1 2018.

McClain Value Management reported no remaining Enanta Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
McClain Value Management sold 37,810 Enanta Pharmaceuticals shares in Q1 2018, an estimated $2.22M.
McClain Value Management first reported a position in Enanta Pharmaceuticals in Q1 2015 and held it in 12 quarters.
McClain Value Management's Enanta Pharmaceuticals position peaked at $19.9M in Q2 2015.
181 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2018.

Based on McClain Value Management's 13F filing for Q1 2018, filed 7 May 2018.